Ferguson Wellman Capital Management Inc. Sells 1,048 Shares of Eli Lilly and Company (NYSE:LLY)

Ferguson Wellman Capital Management Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 4.9% in the third quarter, Holdings Channel reports. The fund owned 20,354 shares of the company’s stock after selling 1,048 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Eli Lilly and Company were worth $18,032,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC lifted its stake in shares of Eli Lilly and Company by 9.2% in the 1st quarter. International Assets Investment Management LLC now owns 13,757 shares of the company’s stock valued at $10,463,000 after purchasing an additional 1,160 shares during the last quarter. Unique Wealth LLC bought a new stake in Eli Lilly and Company in the first quarter worth $260,000. Salem Investment Counselors Inc. boosted its stake in Eli Lilly and Company by 2.8% during the first quarter. Salem Investment Counselors Inc. now owns 72,338 shares of the company’s stock worth $56,276,000 after buying an additional 1,961 shares during the period. Contravisory Investment Management Inc. bought a new position in Eli Lilly and Company during the first quarter valued at $501,000. Finally, Cooper Financial Group raised its stake in shares of Eli Lilly and Company by 16.1% in the first quarter. Cooper Financial Group now owns 1,521 shares of the company’s stock valued at $1,183,000 after acquiring an additional 211 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.1 %

LLY opened at $917.97 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The firm has a market cap of $872.44 billion, a price-to-earnings ratio of 135.19, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock has a fifty day moving average price of $921.21 and a 200-day moving average price of $858.02.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Finally, BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.